Association of Improvement in Pain With Therapeutic Response as Determined by Individual Improvement Criteria in Patients With Rheumatoid Arthritis-Reference-Cited by-同舟云学术

Association of Improvement in Pain With Therapeutic Response as Determined by Individual Improvement Criteria in Patients With Rheumatoid Arthritis

Published:2016-10 Issue:11 Volume:68 Page:1607-1615
ISSN:2151-464X
Container-title:Arthritis Care & Research
language:en
Short-container-title:Arthritis Care & Research

Author:

Scharbatke Eva C.¹,Behrens Frank²,Schmalzing Marc¹,Koehm Michaela²,Greger Gerd³,Gnann Holger⁴,Burkhardt Harald²,Tony Hans‐Peter¹

Affiliation:

1. Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität WürzburgWürzburg Germany

2. University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMPFrankfurt am Main Germany

3. AbbVie Deutschland GmbH & Co. KGWiesbaden Germany

4. Abteilung Biostatistik, GKM Gesellschaft für Therapieforschung mbHMünchen Germany

Funder

AbbVie Deutschland GmbH & Co. KG (formerly Abbott GmbH & Co. KG)

Publisher

Wiley

Subject

Rheumatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/acr.22884

Reference30 articles.

1. Patient- versus physician-reported outcomes in rheumatoid arthritis patients treated with recombinant interleukin-1 receptor antagonist (anakinra) therapy

2. Documenting the Value of Care for Rheumatoid Arthritis, Analogous to Hypertension, Diabetes, and Hyperlipidemia: Is Control of Individual Patient Self-Report Measures of Global Estimate and Physical Function More Valuable Than Laboratory Tests, Radiographs, Indices, or Remission Criteria?

3. Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational study

4. Development and validation of a new DAS28-based treatment response criterion for rheumatoid arthritis

5. Clinimetrics corner: a closer look at the minimal clinically important difference (MCID)

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Safety and Effectiveness of Infliximab Biosimilar in Managing Rheumatoid Arthritis: A Real-Life Experience from Jordan;International Journal of Clinical Practice;2022-08-26

2. Curcumin: Useful add-on for Rheumatic Diseases?;Journal of Clinical Medicine;2022-05-20

3. Does concomitant methotrexate confer clinical benefits in patients treated with prior biologic therapy? Analysis of data from a noninterventional study of rheumatoid arthritis patients initiating treatment with adalimumab;Medicine;2020-05

4. Sustained improvement in work outcomes in employed patients with rheumatoid arthritis during 2 years of adalimumab therapy: an observational cohort study;Clinical Rheumatology;2020-03-23

5. Individual therapeutic DAS28-dcrit responses differentiate between effectiveness of rheumatoid arthritis therapies and reflect patient-reported outcomes: retrospective analysis of DAS28 responses in comparative tocilizumab studies;Rheumatology International;2020-02-10